Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A. Holstein; J. Christine Ye; Alan Howard; Manisha Bhutani; Nicole Gormley; Theresa Hahn; Jens Hillengass; Amrita Krishnan; C. Ola Landgren; Nikhil C. Munshi; Stefania Oliva; Roger G. Owen; Marcelo C. Pasquini; Noemi Puig; Niels Weinhold; Katja Weisel; Philip L. McCarthy

doi:10.1016/j.bbmt.2018.11.001

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A. Holstein, J. Christine Ye, Alan Howard, Manisha Bhutani, Nicole Gormley, Theresa Hahn, Jens Hillengass, Amrita Krishnan, C. Ola Landgren, Nikhil C. Munshi, Stefania Oliva, Roger G. Owen, Marcelo C. Pasquini, Noemi Puig, Niels Weinhold, Katja Weisel, Philip L. McCarthy

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

Original language	English (US)
Pages (from-to)	e89-e97
Journal	Biology of Blood and Marrow Transplantation
Volume	25
Issue number	3
DOIs	https://doi.org/10.1016/j.bbmt.2018.11.001
State	Published - Mar 2019

Keywords

Autologous stem cell transplantation
Endpoint
Immune profiling
Minimal residual disease
Multiple myeloma

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2018.11.001

Cite this

Holstein, S. A., Ye, J. C., Howard, A., Bhutani, M., Gormley, N., Hahn, T., Hillengass, J., Krishnan, A., Landgren, C. O., Munshi, N. C., Oliva, S., Owen, R. G., Pasquini, M. C., Puig, N., Weinhold, N., Weisel, K., & McCarthy, P. L. (2019). Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 25(3), e89-e97. https://doi.org/10.1016/j.bbmt.2018.11.001

Holstein, SA, Ye, JC, Howard, A, Bhutani, M, Gormley, N, Hahn, T, Hillengass, J, Krishnan, A, Landgren, CO, Munshi, NC, Oliva, S, Owen, RG, Pasquini, MC, Puig, N, Weinhold, N, Weisel, K & McCarthy, PL 2019, 'Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling', Biology of Blood and Marrow Transplantation, vol. 25, no. 3, pp. e89-e97. https://doi.org/10.1016/j.bbmt.2018.11.001

@article{a04ff8be21cf4234bb04be2d0269803b,

title = "Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling",

abstract = "The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.",

keywords = "Autologous stem cell transplantation, Endpoint, Immune profiling, Minimal residual disease, Multiple myeloma",

author = "Holstein, {Sarah A.} and Ye, {J. Christine} and Alan Howard and Manisha Bhutani and Nicole Gormley and Theresa Hahn and Jens Hillengass and Amrita Krishnan and Landgren, {C. Ola} and Munshi, {Nikhil C.} and Stefania Oliva and Owen, {Roger G.} and Pasquini, {Marcelo C.} and Noemi Puig and Niels Weinhold and Katja Weisel and McCarthy, {Philip L.}",

note = "Publisher Copyright: {\textcopyright} 2018 American Society for Blood and Marrow Transplantation",

year = "2019",

month = mar,

doi = "10.1016/j.bbmt.2018.11.001",

language = "English (US)",

volume = "25",

pages = "e89--e97",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

AU - Holstein, Sarah A.

AU - Ye, J. Christine

AU - Howard, Alan

AU - Bhutani, Manisha

AU - Gormley, Nicole

AU - Hahn, Theresa

AU - Hillengass, Jens

AU - Krishnan, Amrita

AU - Landgren, C. Ola

AU - Munshi, Nikhil C.

AU - Oliva, Stefania

AU - Owen, Roger G.

AU - Pasquini, Marcelo C.

AU - Puig, Noemi

AU - Weinhold, Niels

AU - Weisel, Katja

AU - McCarthy, Philip L.

PY - 2019/3

Y1 - 2019/3

N2 - The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

AB - The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

KW - Autologous stem cell transplantation

KW - Endpoint

KW - Immune profiling

KW - Minimal residual disease

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85057956613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057956613&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.11.001

DO - 10.1016/j.bbmt.2018.11.001

M3 - Article

C2 - 30408566

AN - SCOPUS:85057956613

SN - 1083-8791

VL - 25

SP - e89-e97

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 3

ER -

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this